Orphan Drug Act

Results: 190



#Item
71The Food and Drug Administration (FDA) convened its first “fDA Rare Disease Patient Advocacy Day” on March 1, 2012

The Food and Drug Administration (FDA) convened its first “fDA Rare Disease Patient Advocacy Day” on March 1, 2012

Add to Reading List

Source URL: www.fda.gov.

Language: English
72July 25, 2014  The Honorable Fred Upton, Chairman U.S. House of Representatives Committee on Energy & Commerce 2125 Rayburn House Office Building

July 25, 2014 The Honorable Fred Upton, Chairman U.S. House of Representatives Committee on Energy & Commerce 2125 Rayburn House Office Building

Add to Reading List

Source URL: www.rarediseases.org

Language: English - Date: 2014-07-28 12:01:38
73DECEMBER[removed]FY 2012 Innovative Drug Approvals Bringing Life-saving Drugs to Patients Quickly and Efficiently http://www.fda.gov/AboutFDA /ReportsManualsForms/Reports/ucm276385.htm

DECEMBER[removed]FY 2012 Innovative Drug Approvals Bringing Life-saving Drugs to Patients Quickly and Efficiently http://www.fda.gov/AboutFDA /ReportsManualsForms/Reports/ucm276385.htm

Add to Reading List

Source URL: www.fda.gov.

Language: English
74THE ECONOMIC POWER OF ORPHAN DRUGS Despite the smaller patient pool for rare disease R&D, the economics of

THE ECONOMIC POWER OF ORPHAN DRUGS Despite the smaller patient pool for rare disease R&D, the economics of

Add to Reading List

Source URL: thomsonreuters.com

Language: English - Date: 2014-01-15 19:42:22
75What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis Chandana Thorat, Kui Xu, Scott N. Freeman, Renan A. Bonnel, Francesca Joseph, M. Ian Phillips and Menfo A. Imoisili Pediatrics;

What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis Chandana Thorat, Kui Xu, Scott N. Freeman, Renan A. Bonnel, Francesca Joseph, M. Ian Phillips and Menfo A. Imoisili Pediatrics;

Add to Reading List

Source URL: pediatrics.aappublications.org

Language: English - Date: 2012-02-22 08:02:14
76FDA Rare Disease Patient Advocacy Day Frank J. Sasinowski, M.S., M.P.H., J.D. Chairman of the Board National Organization for Rare Disorders 1

FDA Rare Disease Patient Advocacy Day Frank J. Sasinowski, M.S., M.P.H., J.D. Chairman of the Board National Organization for Rare Disorders 1

Add to Reading List

Source URL: www.fda.gov

Language: English
77FDA Rare Disease Patient Advocacy Day, Breakout Presentaion

FDA Rare Disease Patient Advocacy Day, Breakout Presentaion

Add to Reading List

Source URL: www.fda.gov

Language: English
78Small Business Assistance: Financial Assistance and Incentives for Research and Development of New Drug/Biologic Products

Small Business Assistance: Financial Assistance and Incentives for Research and Development of New Drug/Biologic Products

Add to Reading List

Source URL: www.fda.gov

Language: English
792013 REPORT  Medicines in Development Rare Diseases

2013 REPORT Medicines in Development Rare Diseases

Add to Reading List

Source URL: www.phrma.org

Language: English - Date: 2013-12-17 14:14:10
80Orphan Drugs The term

Orphan Drugs The term "orphan drug" refers to a product that treats a rare disease affecting fewer than 200,000 Americans. The Orphan Drug Act was signed into law on January 4, 1983. Since the Orphan Drug Act passed, ove

Add to Reading List

Source URL: humansubjects.stanford.edu

Language: English - Date: 2006-11-02 15:22:31